Taipei Exchange - Delayed Quote TWD

Intelligene (7832.TWO)

11.05
-0.45
(-3.91%)
At close: May 29 at 2:56:31 PM GMT+8
Loading Chart for 7832.TWO
  • Previous Close 11.50
  • Open 11.55
  • Bid 11.00 x --
  • Ask 11.10 x --
  • Day's Range 10.95 - 11.55
  • 52 Week Range 4.73 - 16.70
  • Volume 212,475
  • Avg. Volume 1,503,689
  • Market Cap (intraday) 6.409B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.30
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Intelligene Inc. engages in the development of RNA gene therapy drugs for infectious diseases. The company uses siRNA based drugs to develop the treatment of pandemics and influenza. The company was founded in 2023 and is headquartered in Taipei, Taiwan.

www.intelli-gene.com

--

Full Time Employees

--

Fiscal Year Ends

Recent News: 7832.TWO

View More

Performance Overview: 7832.TWO

Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .

YTD Return

7832.TWO
130.21%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
7.33%

1-Year Return

7832.TWO
130.21%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
1.46%

3-Year Return

7832.TWO
130.21%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
31.24%

5-Year Return

7832.TWO
130.21%
TSEC CAPITALIZATION WEIGHTED ST (^TWII)
95.09%

Compare To: 7832.TWO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 7832.TWO

View More

Valuation Measures

Annual
As of 5/29/2025
  • Market Cap

    6.38B

  • Enterprise Value

    5.67B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    1.36k

  • Price/Book (mrq)

    9.60

  • Enterprise Value/Revenue

    3.19k

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    --

  • Diluted EPS (ttm)

    -0.30

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 7832.TWO

View More

Company Insights: 7832.TWO

Research Reports: 7832.TWO

View More